Relay Therapeutics Reports Interim Data for Breast Cancer Treatment
Relay Therapeutics Reports Interim Data for Breast Cancer Treatment
Relay Therapeutics, Inc. (NASDAQ:RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced positive interim data for RLY-2608, the first known investigational allosteric, pan-mutant and isoform-selective inhibitor of PI3Kα. The data showed that despite heavy pre-treatment, patients with PI3Kα-mutated, HR+, HER2- locally advanced or metastatic breast cancer who received RLY-2608 600mg BID + fulvestrant demonstrated clinically meaningful progression free survival (PFS).
Relay Therapeutics, Inc.（納斯達克股票代碼：RLAY）是一家臨床階段的精準醫療公司，通過結合尖端的計算和實驗技術來改變藥物發現過程。該公司今天公佈了PI3Kα的首個已知在研變構、泛突變體和異形選擇性抑制劑 RLY-2608 的積極中期數據。數據顯示，儘管進行了大量的預治療，但接受了 RLY-2608 600mg BID + fulvestrant 的 PI3Kα突變、HR+、HER2-局部晚期或轉移性乳腺癌患者表現出具有臨床意義的無進展存活率（PFS）。
